ResMed stock is down today, even though the maker of CPAPs and other respiratory treatment devices had Street-beating Q2 ...

Shares of ResMed (NYSE:RMD) fell 6% today, despite the company reporting second-quarter earnings that surpassed analyst ...

ResMed reported robust earnings for the second quarter of fiscal 2025, surpassing expectations and showcasing strong growth ...

Shares of ResMed Inc. shed 8.33% to $236.18 Friday, on what proved to be an all-around dismal trading session for the ...

Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD – Research Report) received a Buy rating and price target from ...

ResMed’s (ASX:RMD) half-year FY25 results reflect a company that is not only thriving in its core business but is also ...

ResMed beat Wall Street estimates for second-quarter profit on Thursday, driven by strong demand for its devices used to manage sleep apnea, a common sleep disorder.

ResMed Inc. (NYSE:RMD – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the fifteen ratings firms that are covering the firm, Marketbeat.com reports. One research ...

ResMed's 10.2% revenue jump in Q2 was driven by strong demand for sleep health products, with a particular focus on expansion in digital health platforms. The 29.3% year-over-year bump up in ...

Wilsons analyst Shane Storey downgraded Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD – Research Report) to a ...